Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on August 23, 2019, 10:31:59 am
-
The introduction of Gilead Sciences’ hepatitis C virus (HCV) Sovaldi (sofosbuvir) to the market in December 2013 was associated with improvements in the health outcomes of those living with the virus who were on the liver transplant waiting list.
Sovaldi ushered in the current era of highly effective direct-acting antiviral (DAA) treatment. The drug was incorporated into Gilead’s Harvoni (ledipasvir/sofosbuvir), which was approved in October 2014 and became a blockbuster drug. Various other DAAs from other pharmaceutical companies emerged from the pipeline during this time, leading to today’s healthy crop of numerous, highly effective hep C regimens.
For more...
https://www.hepmag.com/article/sovaldis-arrival-tied-better-outcomes-liver-transplant-waiting-list